Notice2026-04103
Impact on U.S. Industry of China's State Support and Pricing Practices in the Biotechnology Sector
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 2, 2026
Issuing agencies
International Trade Commission
Abstract
The U.S. International Trade Commission has self-instituted Investigation No. 332-610, Impact on U.S. Industry of China's State Support and Pricing Practices in the Biotechnology Sector, to produce a report as directed by the U.S. Senate Committee on Appropriations reviewing the extent to which Chinese state support and pricing practices in the biotechnology sector may be affecting market share and competitiveness of the U.S. industry.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 40 (Monday, March 2, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 40 (Monday, March 2, 2026)]
[Notices]
[Pages 10153-10155]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-04103]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 332-610]
Impact on U.S. Industry of China's State Support and Pricing
Practices in the Biotechnology Sector
AGENCY: United States International Trade Commission.
ACTION: Notice of investigation and scheduling of a public hearing.
-----------------------------------------------------------------------
SUMMARY: The U.S. International Trade Commission has self-instituted
Investigation No. 332-610, Impact on U.S. Industry of China's State
Support and Pricing Practices in the Biotechnology Sector, to produce a
report as directed by the U.S. Senate Committee on Appropriations
reviewing the extent to which Chinese state support and pricing
practices in the biotechnology sector may be affecting market share and
competitiveness of the U.S. industry.
DATES:
May 11, 2026: Deadline for filing requests to appear at the public
hearing.
May 14, 2026: Deadline for filing prehearing briefs and statements.
May 20, 2026: Deadline for filing electronic copies of hearing oral
statements.
May 27-28, 2026: Public hearing.
June 11, 2026: Deadline for filing posthearing briefs.
July 17, 2026: Deadline for filing all other written submissions.
January 22, 2027: Anticipated date for publication of the report.
ADDRESSES: All Commission offices, including the Commission's hearing
rooms, are located in the U.S. International Trade Commission Building,
500 E Street SW, Washington, DC 20436. All written submissions should
be addressed to the Secretary, U.S. International Trade Commission, 500
E Street SW, Washington, DC 20436. The public record for this
investigation may be viewed on the Commission's electronic docket
(EDIS) at <a href="https://edis.usitc.gov">https://edis.usitc.gov</a>.
FOR FURTHER INFORMATION CONTACT: Project Leader Nathan Lotze (202-205-
3231 or <a href="/cdn-cgi/l/email-protection#b4dad5c0dcd5da9ad8dbc0ced1f4c1c7ddc0d79ad3dbc2"><span class="__cf_email__" data-cfemail="f69897829e9798d89a99828c93b683859f8295d8919980">[email protected]</span></a>) or Deputy Project Leaders Lin Jones
(202-205-3246 or <a href="/cdn-cgi/l/email-protection#f4989d9ada9e9b9a9187b481879d8097da939b82"><span class="__cf_email__" data-cfemail="64080d0a4a0e0b0a01172411170d10074a030b12">[email protected]</span></a>) and Grace Robinson (202-205-3711
or <a href="/cdn-cgi/l/email-protection#6a0d180b090f4418050803041905042a1f19031e09440d051c"><span class="__cf_email__" data-cfemail="e28590838187cc908d808b8c918d8ca297918b9681cc858d94">[email protected]</span></a>) for information specific to this
investigation. For information on the legal aspects of this
investigation, contact Brian Allen (202-205-3034 or
<a href="/cdn-cgi/l/email-protection#1371617a727d3d727f7f767d5366607a67703d747c65"><span class="__cf_email__" data-cfemail="5634243f373878373a3a33381623253f223578313920">[email protected]</span></a>) of the Commission's Office of the General
Counsel. The media should contact Claire Huber, Office of External
Relations (202-205-1819 or <a href="/cdn-cgi/l/email-protection#a6c5cac7cfd4c388ced3c4c3d4e6d3d5cfd2c588c1c9d0"><span class="__cf_email__" data-cfemail="7b18171a12091e55130e191e093b0e08120f18551c140d">[email protected]</span></a>). Hearing-impaired
individuals may obtain information on this matter by contacting the
Commission's TDD terminal at 202-205-1810. General information
concerning the Commission may also be obtained by accessing its website
(<a href="https://www.usitc.gov">https://www.usitc.gov</a>). Persons with mobility impairments who will
need special assistance in gaining access to the Commission should
contact the Office of the Secretary at 202-205-2000.
SUPPLEMENTARY INFORMATION:
Background: The Commerce, Justice, Science; Energy and Water
Development; and Interior and Environment Appropriations Act, 2026 (the
Act), signed by the President on January 23, 2026, provides funding for
the Commission for fiscal year 2026. Public Law 119-74. A report of the
Senate Committee on Appropriations (Committee) accompanying the Act
contains language directing the Commission to review the extent to
which Chinese state support and pricing practices in the biotechnology
sector may be affecting U.S. market share and competitiveness. The
Committee in its
[[Page 10154]]
report states that the Commission report in this investigation (1)
should include detailed information, to the extent practicable, on the
degree of subsidization and market overcapacity by Chinese
biotechnology firms and its impact on U.S. industry, including genomic
sequencing, synthetic biology, and active pharmaceutical ingredient
manufacturing; (2) should examine the extent to which Chinese state
support and pricing practices may be affecting U.S. market share and
competitiveness in biotechnology-related products and services; and (3)
should be transmitted to the House of Representatives and Senate
Committees on Appropriations within 12 months of the Act's enactment.
Departments of Commerce and Justice, Science, and Related Agencies
Appropriations Bill, S. Rept. No. 119-44, at 174-75 (2025); 172 Cong.
Rec. H255 (daily ed. Jan. 8, 2026).
The Commission is self-instituting this investigation under section
332(b) of the Trade Act of 1974 (19 U.S.C. 1332(b)) to produce a report
containing information and analysis as detailed above and will publish
its report no later than January 22, 2027.
Public hearing: A public hearing in connection with this
investigation will be held beginning at 9:30 a.m., May 27, 2026, and
continuing, if necessary, on May 28, 2026, in the Main Hearing Room of
the U.S. International Trade Commission, 500 E Street SW, Washington,
DC 20436. The hearing can also be accessed remotely using the WebEx
videoconference platform. A link to the hearing will be posted on the
Commission's website at <a href="https://www.usitc.gov/calendarpad/calendar.html">https://www.usitc.gov/calendarpad/calendar.html</a>.
Requests to appear at the hearing should be filed with the
Secretary to the Commission no later than 5:15 p.m., May 11, 2026, in
accordance with the requirements in the ``Written Submissions'' section
below. Any requests to appear as a witness via videoconference must be
included with your request to appear. Requests to appear as a witness
via videoconference must include a statement explaining why the witness
cannot appear in person; the Chair, or other person designated to
conduct the investigation, may at their discretion for good cause
shown, grant such requests. Requests to appear as a witness via
videoconference due to illness or a positive COVID-19 test result may
be submitted by 3 p.m. the business day prior to the hearing.
All prehearing briefs and statements should be filed no later than
5:15 p.m., May 14, 2026. To facilitate the hearing, including the
preparation of an accurate written public transcript of the hearing, a
written copy of oral testimony to be presented at the hearing must be
submitted to the Commission electronically no later than noon, May 20,
2026. All posthearing briefs and statements should be filed no later
than 5:15 p.m., June 11, 2026. Posthearing briefs and statements should
address matters raised at the hearing. For a description of the
different types of written briefs and statements, see the
``Definitions'' section below.
In the event that, as of the close of business on May 11, 2026, no
witnesses are scheduled to appear at the hearing, the hearing will be
canceled. Any person interested in attending the hearing as an observer
or nonparticipant should check the Commission website as indicated
above for information concerning whether the hearing will be held.
Written submissions: In lieu of or in addition to participating in
the hearing, interested persons are invited to file written submissions
concerning this investigation. All written submissions should be
addressed to the Secretary, and should be received no later than 5:15
p.m., July 17, 2026. All written submissions must conform to the
provisions of section 201.8 of the Commission's Rules of Practice and
Procedure (19 CFR 201.8). Filings must be made through the Commission's
Electronic Document Information System (EDIS, <a href="https://edis.usitc.gov">https://edis.usitc.gov</a>).
Persons with questions regarding electronic filing should contact the
Office of the Secretary, Docket Services Division (202-205-1802), email
<a href="/cdn-cgi/l/email-protection#c184858892f2a9a4adb181b4b2a8b5a2efa6aeb7"><span class="__cf_email__" data-cfemail="93d6d7dac0a0fbf6ffe3d3e6e0fae7f0bdf4fce5">[email protected]</span></a>, or consult the Commission's Handbook on Filing
Procedures.
Definitions of types of documents that may be filed; Requirements:
In addition to requests to appear at the hearing, this notice provides
for the possible filing of four types of documents: prehearing briefs,
hearing oral statements, posthearing briefs, and other written
submissions.
(1) Prehearing briefs refers to written materials relevant to the
investigation and submitted in advance of the hearing, and includes
written views on matters that are the subject of the investigation,
supporting materials, and any other written materials that you consider
will help the Commission in understanding your views. You should file a
prehearing brief particularly if you plan to testify at the hearing on
behalf of an industry group, company, or other organization, and wish
to provide detailed views or information that will support or
supplement your testimony.
(2) Hearing oral statements refers to the actual oral statement
that you intend to present at the hearing. Do not include any
confidential business information (CBI) in that statement. If you plan
to testify, you must file a written copy of your oral statement by the
date specified in this notice. This statement will allow Commissioners
to understand your position in advance of the hearing and will also
assist the court reporter in preparing an accurate transcript of the
hearing (e.g., names spelled correctly).
(3) Posthearing briefs refers to submissions filed after the
hearing by persons who appeared at the hearing. Such briefs: (a) should
be limited to matters that arose during the hearing; (b) should respond
to any Commissioner and staff questions addressed to you at the
hearing; (c) should clarify, amplify, or correct any statements you
made at the hearing; and (d) may, at your option, address or rebut
statements made by other participants in the hearing.
(4) Other written submissions refers to any other written
submissions that interested persons wish to make, regardless of whether
they appeared at the hearing, and may include new information or
updates of information previously provided.
In accordance with the provisions of section 201.8 of the
Commission's Rules of Practice and Procedure, the document must
identify on its cover (1) the investigation number and title and the
type of document filed (i.e., prehearing brief, hearing oral statement
of (name), posthearing brief, or written submission); (2) the name and
signature of the person filing it; (3) the name of the organization
that the submission is filed on behalf of; and (4) whether it contains
CBI. If it contains CBI, it must comply with the marking and other
requirements set out below in this notice relating to CBI. Submitters
of written documents (other than hearing oral statements) are
encouraged to include a short summary of their position or interest at
the beginning of the document, and a table of contents when the
document addresses multiple issues.
Confidential business information: Any submissions that contain CBI
must also conform to the requirements of section 201.6 of the
Commission's Rules of Practice and Procedure (19 CFR 201.6). Section
201.6 of the rules requires that the cover of the document and the
individual pages be clearly marked as to whether they are the
``confidential'' or ``nonconfidential'' version, and that the CBI is
clearly identified by means of brackets. All written submissions,
except for CBI, will be made available for inspection by interested
persons.
[[Page 10155]]
The Commission will not include any CBI in its report. However, all
information, including CBI, submitted in this investigation may be
disclosed to and used by: (i) the Commission, its employees and
offices, and contract personnel (a) for developing or maintaining the
records of this or a related proceeding, or (b) in internal
investigations, audits, reviews, and evaluations relating to the
programs, personnel, and operations of the Commission, including under
5 U.S.C. Appendix 3; or (ii) U.S. government employees and contract
personnel for cybersecurity purposes. The Commission will not otherwise
disclose any CBI in a way that would reveal the operations of the firm
supplying the information.
Summaries of views of interested persons: Interested persons
wishing to have a summary of their views included in the report should
include a summary with a written submission on or before July 17, 2026,
and should mark the summary as having been provided for that purpose.
The summary should be clearly marked as ``summary for inclusion in the
report'' at the top of the page. The summary may not exceed 500 words
and should not include any CBI. The summary will be published as
provided if it meets these requirements and is germane to the subject
matter of the investigation. The Commission will list the name of the
organization furnishing the summary and will include a link where the
written submission can be found.
By order of the Commission.
Issued: February 26, 2026.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2026-04103 Filed 2-27-26; 8:45 am]
BILLING CODE 7020-02-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 2, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.